Sebastian A. Nunez

B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.

Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 03, 2026

Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.

Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 02, 2025

Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.

Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.

Journal: Human vaccines & immunotherapeutics

Published: November 06, 2025

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.

Journal: EClinicalMedicine

Published: May 21, 2025

Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial.

Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial.

Journal: Vaccine

Published: November 15, 2024

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: February 29, 2024

Serological response to SARS-CoV-2 vaccines in patients with multiple sclerosis in Argentina.

Serological response to SARS-CoV-2 vaccines in patients with multiple sclerosis in Argentina.

Journal: Medicina

Published: June 28, 2023

Computational assessment of lipid production in Rhodosporidium toruloides in two-stage and one-stage batch bioprocesses.

Computational assessment of lipid production in Rhodosporidium toruloides in two-stage and one-stage batch bioprocesses.

Journal: Biotechnology and bioengineering

Published: March 23, 2023

Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs.

Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs.

Journal: Multiple sclerosis and related disorders

Published: January 08, 2023

Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM.

Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM.

Journal: Multiple sclerosis and related disorders

Published: May 26, 2022

Extended SEIR Model for Health Policies Assessment Against the COVID-19 Pandemic: the Case of Argentina.

Extended SEIR Model for Health Policies Assessment Against the COVID-19 Pandemic: the Case of Argentina.

Journal: Journal of healthcare informatics research

Published: April 01, 2021

COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.

COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.

Journal: Multiple sclerosis and related disorders

Published: December 31, 2020

Showing 1-12 of 17

Last Updated: 09/26/2026